A Non-randomized, Exploratory, Study to Assess Clinical Response to Gilenya® (Fingolimod) in a Cohort of Relapsing Remitting Hispanic MS Forms
Phase of Trial: Phase IV
Latest Information Update: 07 May 2018
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 29 Mar 2017 Planned End Date changed from 1 Oct 2014 to 1 Oct 2017.
- 29 Mar 2017 Planned primary completion date changed from 1 Apr 2014 to 1 Jul 2017.